This approval positions Lupin to tap into a substantial market opportunity for a drug indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune neuromuscular disorder, the company said in a filing.
This approval positions Lupin to tap into a substantial market opportunity for a drug indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune neuromuscular disorder, the company said in a filing.